Facts
as of Nov 20, 2026
Invivyd is on a mission to rapidly and continually deliver antibody-based therapies that keep pace with the evolving viral threats.
It is hiring: 7 open roles, 0 of them posted in the last 30 days.
- Legal name
- Invivyd, Inc.
- Headquarters
- New Haven, United States
- Founded
- 2020
- Employees
- 118US Form 5500 (plan participants) · Dec 2025 · +33% in a year
- Listing
- NASDAQ: IVVD
- Register numbers
- EIN 851403134
As of Nov 20, 2026, Alion lists 7 open roles at Invivyd. Invivyd is headquartered in New Haven, United States. It was founded in 2020. The median pay stated in its open roles is $202k, across 7 postings that state pay.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Invivyd: 3 money records, each linked to its source.
$155kCapital expenditureFY2025
Revenue by yearas filed, with the net income
2025$53.4Mnet income −$52.5M
2024$25.4Mnet income −$169.9M
2023$0net income −$198.6M
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Invivyd operates through 2 legal entities in 1 country.
Legal entities2 in 1 country
Invivyd, Inc.
operator · US EIN 851403134
US
Adagio Therapeutics, Inc.
operator
US
Holders and shares as each register or filing states them.
7 open roles, 0 of them posted in the last 30 days.
7Open roles
$202kMedian advertised pay$160k – $245k
34 daysTime to fillmarket: 34 days
118EmployeesUS Form 5500 (plan participants) · Dec 2025 · +33% in a year
Head countas filed and stated
Where the openings areshare of open roles
Open roles over time−13%
Sep 14This week
Open roles a week: 8 then, 7 now
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family
Invivyd has 9 clinical trials on record, 3 under way.
top 6%Web presenceof 133.2M domains by links, Common Crawl
Clinical trials
Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome
phase 2 · under way · 130 participants · Long COVID; COVID-19 (SARS-CoV-2 Infection); COVID 19 Vaccine; COVID Long
Oct 2026
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With …
phase 3 · completed · 210 participants · COVID-19
Jun 2026
Study of VYD2311 for the Prevention of COVID-19
phase 3 · under way · 1,770 participants · COVID-19
Jan 2026
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
Invivyd: $20k of EU lobbying in 2025, 1 federal court cases.
Legal entity active
Invivyd, Inc.
Not checked
Postings are real
Alion truth index: B
75/100
Ghost roles
re-checked against its careers site
0%
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Court cases
Jan 2023 – Jan 2023 · 1 as defendant · 1 closed
1
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Milestones
Team of 118 was 89 · US Form 5500 (plan participants)
2025
Newsroom
Press releaseYahooFinance
Sep 23
NewsInvivyd stock falls 8 percent as earnings miss estimates
Sep 23
Sources: the outlets named on each headline, each story once
Ranked #9 by open roles among its 11 closest peers.
Source: Alion's similar-companies engine (industry segments, technologies, headquarters country, size)
Tech stack
The technologies known for Invivyd, by layer.
Sign in to see how your skills match this stackSign In
Source: the technologies named in the company's postings and on its site